Joe Sulovski serves as the Vice President of Clinical Operations at Inimmune Corporation, bringing over 20 years of leadership experience in clinical research across oncology, immunology, and vaccine therapeutics. His career is distinguished by a focus on advancing innovative clinical development strategies and aligning operational priorities with organizational goals.

At Inimmune, Joe plays a pivotal role in driving the success of allergy and oncology programs, fostering collaboration across teams and ensuring excellence in trial execution. His ability to effectively communicate clinical development plans to stakeholders has been instrumental in securing support for critical initiatives.

Throughout his career at both large pharma and small biotech companies, Joe has demonstrated a deep commitment to building high-performing teams and advancing clinical innovations.. In previous positions, he successfully led the transition from a consultant-based clinical model to an in-house team, delivering multiple Phase 1 and Phase 2 vaccine trials for Meissa Vaccines, and has built Clinical Development and Operations teams from the ground up, advancing Chromocell Corporoation’s first investigational drug.

Joe holds a Bachelor of Science in Biology from the University of Maryland and a Mini-MBA in BioPharm Innovations from Rutgers University. He is highly skilled in clinical trial oversight, regulatory compliance, team leadership, and therapeutic expertise, making him a key contributor to Inimmune’s mission of delivering groundbreaking immunomodulatory therapies.